Cargando…
Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is an incurable lung disease with a poor prognosis. Fibroblasts and myofibroblasts are the key cells in the fibrotic process. Recently two drugs, pirfenidone and nintedanib, were approved for clinical use as they are able to slow down the disease progr...
Autores principales: | Lehtonen, Siri T., Veijola, Anniina, Karvonen, Henna, Lappi-Blanco, Elisa, Sormunen, Raija, Korpela, Saara, Zagai, Ulrika, Sköld, Magnus C., Kaarteenaho, Riitta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743320/ https://www.ncbi.nlm.nih.gov/pubmed/26846335 http://dx.doi.org/10.1186/s12931-016-0328-5 |
Ejemplares similares
-
Myofibroblast expression in airways and alveoli is affected by smoking and COPD
por: Karvonen, Henna M, et al.
Publicado: (2013) -
Pharmacological treatment of idiopathic pulmonary fibrosis – preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine
por: Myllärniemi, Marjukka, et al.
Publicado: (2015) -
Epithelial N-cadherin and nuclear β-catenin are up-regulated during early development of human lung
por: Kaarteenaho, Riitta, et al.
Publicado: (2010) -
Tenascin-C and alpha-smooth muscle actin positive cells are increased in the large airways in patients with COPD
por: Löfdahl, Magnus, et al.
Publicado: (2011) -
Tissue is an issue in the search for biomarkers in idiopathic pulmonary fibrosis
por: Kaarteenaho, Riitta, et al.
Publicado: (2015)